Table 2.
Antibody Status Before and After Vaccination With Bivalent mRNA SARS-CoV-2 Vaccines in Participants With Different Levels of Immunosuppression, Measured With the Elecsys Anti-SARS-CoV-2 S Assay From Roche
| People with HIV | Solid Organ Transplant Recipients | |||||
|---|---|---|---|---|---|---|
| Antibody status | CD4 < 350 Cells/µL (n = 20) | CD4 ≥ 350 Cells/µL (n = 92) | All (n = 112) | Kidney (n = 22) | Lung (n = 40) | All (n = 62) |
| Baseline | ||||||
| Antibody response, cutoff ≥1642 units/mL | 75 (15/20) | 89 (81/91) | 87 (96/111) | 77 (17/22) | 47 (18/38) | 58 (35/60) |
| Antibody response, cutoff ≥100 units/mL | 90 (18/20) | 100 (91/91) | 98 (109/111) | 100 (22/22) | 84 (32/38) | 90 (54/60) |
| Antibody response, cutoff ≥0.8 units/mL | 100 (20/20) | 100 (91/91) | 100 (111/111) | 100 (22/22) | 92 (35/38) | 95 (57/60) |
| Geometric mean concentration (IQR)a | 4398 (1406–13 764) | 8992 (6899–11 721) | 7955 (5965–10 608) | 5102 (1819–14 310) | 1226 (491–3061) | 1865 (907–3836) |
| 4 weeks follow-up | ||||||
| Antibody response, cutoff ≥1642 units/mL | 85 (69–100) 17/20 | 100 (NA) 86/86 | 97 (94–100) 103/106 | 95 (86–100) 20/21 | 64 (49–80) 23/36 | 75 (64–87) 43/57 |
| Antibody response, cutoff ≥100 units/mL | 95 (85–100) 19/20 | 100 (NA) 86/86 | 99 (97–100) 105/106 | 100 (NA) 21/21 | 83 (71–96) 30/36 | 89 (82–97) 51/57 |
| Antibody response, cutoff ≥0.8 units/mL | 100 (NA) 20/20 | 100 (NA) 86/86 | 100 (NA) 106/106 | 100 (NA) 21/21 | 92 (83–100) 33/36 | 95 (89–100) 54/57 |
| Geometric mean concentration (IQR)a | 32 342 (12 638–82 766) | 53 461 (44 474–62 264) | 48 837 (39 209–60 830) | 23 956 (8098–70 872) | 3108 (1137–8499) | 5772 (2556–13 030) |
| 8 weeks follow-up | ||||||
| Antibody response, cutoff ≥1642 units/mL | 94 (84–100) 17/18 | 99 (96–100) 82/83 | 98 (95–100) 99/101 | 95 (87–100) 21/22 | 61 (45–77) 22/36 | 74 (63–85) 43/58 |
| Antibody response, cutoff ≥100 units/mL | 100 (NA) 18/18 | 100 (NA) 83/83 | 100 (NA) 101/101 | 100 (NA) 22/22 | 89 (79–99) 32/36 | 93 (87–100) 54/58 |
| Antibody response, cutoff ≥0.8 units/mL | 100 (NA) 18/18 | 100 (NA) 83/83 | 100 (NA) 101/101 | 100 (NA) 22/22 | 92 (83–100) 33/36 | 95 (89–100) 55/58 |
| Geometric mean concentration (IQR)a | 27 852 (15 583–49 781) | 36 581 (29 366–45 568) | 34 939 (28 505–42 826) | 23 462 (7651–71 947) | 4216 (1631–10 898) | 7208 (3362–15 454) |
| 6 months follow-up | ||||||
| Antibody response, cutoff ≥1642 units/mL | 82 (64–100) 14/17 | 99 (97–100) 82/83 | 96 (92–100) 96/100 | 95 (86–100) 20/21 | 71 (56–86) 25/35 | 80 (70–91) 45/56 |
| Antibody response, cutoff ≥100 units/mL | 100 (NA) 17/17 | 100 (NA) 83/83 | 100 (NA) 100/100 | 100 (NA) 21/21 | 91 (82–100) 32/35 | 95 (89–100) 53/56 |
| Antibody response, cutoff ≥0.8 units/mL | 100 (NA) 17/17 | 100 (NA) 83/83 | 100 (NA) 100/100 | 100 (NA) 21/21 | 94 (86–100) 33/35 | 96 (92–100) 54/56 |
| Geometric mean concentration (IQR)a | 12 426 (5846–26 412) | 18 088 (14 577–22 446) | 17 036 (13 774–21 071) | 12 899 (4535–36 695) | 5722 (3142–10 421) | 7438 (4459–12 407) |
Data are presented as “% (No./No)” at baseline and “% (95% confidence interval) No./No” at follow-up.
Abbreviations: IQR, interquartile range; NA, not applicable.
aExcluding study samples from the University Hospital Basel center as the measuring range was up to 2500 units/mL (ie, patients with HIV: n = 2 with CD4 < 350 cells/µL CD4; n = 4 with CD4 ≥ 350 cells/µL; n = 12 kidney transplant recipients; and n = 14 lung transplant recipients).